Vivos Therapeutics, Inc.

As of August 27, 2025, Vivos Therapeutics, Inc. shows a mildly bullish trend, supported by daily moving averages and monthly MACD, but caution is advised due to mildly bearish weekly MACD and Dow Theory, with the stock underperforming the S&P 500 year-to-date by -22.14%.

As of June 17, 2025, Vivos Therapeutics, Inc. shows a mildly bearish trend influenced by daily moving averages, while weekly indicators suggest some underlying strength, resulting in mixed signals across different timeframes.

Vivos Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $4 million as of March 2025. The company has a market cap of $12.72 million and key metrics indicate it is currently loss-making with no dividend yield.

As of Jun 18, Vivos Therapeutics, Inc. has a market capitalization of 12.72 million, with net sales of 14.63 million and a net profit of -11.24 million over the latest four quarters. The company has shareholder's funds of 7.95 million and total assets of 15.28 million as of Dec 24.